Pencil Biosciences

Executive Summary

Pencil Biosciences is a UK-based biotechnology company developing a next-generation, fully synthetic gene editing platform that does not rely on CRISPR. Founded in 2018 and headquartered in Cambridge, the company's modular system edits DNA without causing breaks or nicks, potentially offering greater precision and safety for therapeutic and cell line engineering applications. While still in early stages with no disclosed funding or pipeline, its non-CRISPR approach addresses key limitations of current gene editing technologies, such as off-target effects and DNA damage. The platform's synthetic nature could enable more predictable and controllable edits, opening opportunities in gene therapy and synthetic biology. However, the company operates in a competitive landscape with established CRISPR-based players, and its progress remains largely undisclosed, requiring validation through preclinical data or partnerships.

Upcoming Catalysts (preview)

• Q4 2026Proof-of-concept in vivo data30% success
• Q1 2027Series A funding round40% success
• H2 2027Strategic partnership with a pharma company25% success